Print

REGiMMUNE Receives $12 Million in Grants to Develop Transplant and Allergy Drugs  
12/8/2008 11:59:24 AM

MOUNTAIN VIEW, CA and TOKYO--(Marketwire - December 08, 2008) - REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO). Under terms outlined in the five-year grant from JST, REGiMMUNE will develop its reVax drug for cedar allergy; and the three-year grant from NIBIO will fund the development of its ToleroVax drug (RGI-2001), a new immunosuppressant for Graft-versus-Host Disease (GvHD) associated with stem cell transplantation.
//-->